These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 10516644)

  • 1. Novel strategies for the design of receptor-selective vasopressin analogues: Aib-substitution and retro-inverso transformation.
    Howl J; Prochazka Z; Wheatley M; Slaninová J
    Br J Pharmacol; 1999 Oct; 128(3):647-52. PubMed ID: 10516644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
    Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonists.
    Manning M; Cheng LL; Stoev S; Klis W; Nawrocka E; Olma A; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1997; 3(1):31-46. PubMed ID: 9230469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally-restricted, polar and charged amino acids.
    Stoev S; Cheng LL; Olma A; Klis WA; Manning M; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1999 Mar; 5(3):141-53. PubMed ID: 10323558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Position 4 analogues of [deamino-Cys(1)] arginine vasopressin exhibit striking species differences for human and rat V(2)/V(1b) receptor selectivity.
    Guillon G; Pena A; Murat B; Derick S; Trueba M; Ventura MA; Szeto HH; Wo N; Stoev S; Cheng LL; Manning M
    J Pept Sci; 2006 Mar; 12(3):190-8. PubMed ID: 16130178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists.
    Manning M; Cheng LL; Klis WA; Balaspiri L; Olma A; Sawyer WH; Wo NC; Chan WY
    J Med Chem; 1995 May; 38(10):1762-9. PubMed ID: 7752199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent V2/V1a vasopressin antagonists with C-terminal ethylenediamine-linked retro-amino acids.
    Manning M; Przybylski J; Grzonka Z; Nawrocka E; Lammek B; Misicka A; Cheng LL; Chan WY; Wo NC; Sawyer WH
    J Med Chem; 1992 Oct; 35(21):3895-904. PubMed ID: 1433200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
    Pena A; Murat B; Trueba M; Ventura MA; Wo NC; Szeto HH; Cheng LL; Stoev S; Guillon G; Manning M
    J Med Chem; 2007 Feb; 50(4):835-47. PubMed ID: 17300166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of oxytocin antagonists, which are more selective than atosiban.
    Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
    J Pept Sci; 2001 Sep; 7(9):449-65. PubMed ID: 11587184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probing the V1a vasopressin receptor binding site with pyroglutamate-substituted linear antagonists.
    Howl J; Yarwood NJ; Stock D; Wheatley M
    Neuropeptides; 1996 Feb; 30(1):73-9. PubMed ID: 8868303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological characterization of linear analogues of vasopressin generated by the systematic substitution of positions 1 and 6 by L-amino acids.
    Howl J; Filer AD; Parslow RA; Kirk CJ; Jurzak M; Smith AI; Wheatley M
    Biochem Pharmacol; 1994 Apr; 47(9):1497-501. PubMed ID: 8185660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and design of novel and selective vasopressin and oxytocin agonists and antagonists: the role of bioassays.
    Chan WY; Wo NC; Stoev ST; Cheng LL; Manning M
    Exp Physiol; 2000 Mar; 85 Spec No():7S-18S. PubMed ID: 10795902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Properties of a new radioiodinated antagonist for human vasopressin V2 and V1a receptors.
    Ala Y; Morin D; Mahé E; Cotte N; Mouillac B; Jard S; Barberis C; Tribollet E; Dreifuss JJ; Sawyer WH; Wo NC; Chan WY; Kolodziejczyk AS; Cheng LL; Manning M
    Eur J Pharmacol; 1997 Jul; 331(2-3):285-93. PubMed ID: 9274991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surprising pharmacological activity of analogues designed by substitution of position 3 in arginine vasopressin (AVP) and 8-D-arginine vasopressin with L-2-napthylalanine.
    Lammek B; Konieczna E; Trzeciak HI; Kozłowski A; Szymkowiak J; Stojko R; Kupryszewski G
    J Pharm Pharmacol; 1996 Mar; 48(3):316-9. PubMed ID: 8737061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of 1-aminocyclohexane-1-carboxylic acid in position 2 or 3 of AVP and its analogues on their pharmacological properties.
    Jastrzebska B; Derdowska I; Kowalczyk W; Machova A; Slaninová J; Lammek B
    J Pept Res; 2003 Aug; 62(2):70-7. PubMed ID: 12823619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly potent 1-aminocyclohexane-1-carboxylic acid substituted V2 agonists of arginine vasopressin.
    Kowalczyk W; Prahl A; Derdowska I; Dawidowska O; Slaninová J; Lammek B
    J Med Chem; 2004 Nov; 47(24):6020-4. PubMed ID: 15537356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.
    Serradeil-Le Gal C; Wagnon J; Garcia C; Lacour C; Guiraudou P; Christophe B; Villanova G; Nisato D; Maffrand JP; Le Fur G
    J Clin Invest; 1993 Jul; 92(1):224-31. PubMed ID: 8392086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
    Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
    Yamamura Y; Nakamura S; Itoh S; Hirano T; Onogawa T; Yamashita T; Yamada Y; Tsujimae K; Aoyama M; Kotosai K; Ogawa H; Yamashita H; Kondo K; Tominaga M; Tsujimoto G; Mori T
    J Pharmacol Exp Ther; 1998 Dec; 287(3):860-7. PubMed ID: 9864265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel approach to the design of synthetic radioiodinated linear V1A receptor antagonists of vasopressin.
    Manning M; Bankowski K; Barberis C; Jard S; Elands J; Chan WY
    Int J Pept Protein Res; 1992; 40(3-4):261-7. PubMed ID: 1478783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.